Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 6, 2010, Pages 1117-1122

  Katamura, Yoshio ^a   Aikata, Hiroshi ^a   Kimura, Yuki ^a   Kawaoka, Tomokazu ^a   Takaki, Shintaro ^a   Waki, Koji ^a   Hiramatsu, Akira ^a   Kawakami, Yoshiiku ^a   Takahashi, Shoichi ^a   Ishikawa, Masaki ^b   Hieda, Masashi ^b   Kakizawa, Hideaki ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil interferon; Extrahepatic metastases; Hepatocellular carcinoma; Interferon; Portal vein tumor thrombosis

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT PROTEIN; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ANEMIA; APPETITE DISORDER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EXTRAHEPATIC METASTASIS; FEMALE; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; NAUSEA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VASCULAR TUMOR; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; DRUG COMBINATION; FOLLOW UP; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME; TUMOR EMBOLISM; VENOUS THROMBOSIS; VERY ELDERLY; YOUNG ADULT; CANCER PROGNOSIS; FEVER; LOSS OF APPETITE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PORTAL VEIN; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TIME TO PROGRESSION; TUMOR THROMBUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRA-ARTERIAL; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 77953003786     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06110.x     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 : 74 108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006 24 : 2137 2150.
3. Okita K. Management of hepatocellular carcinoma in Japan. J. Gastroenterol. 2006 41 : 100 106.
4. Kamada K, Kitamoto M, Aikata H et al. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am. J. Surg. 2002 184 : 284 290.
5. Kawaoka T, Aikata H, Takaki S et al. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009 32 : 687 694.
6. Rossi S, Di Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am. J. Roentgenol. 1996 167 : 759 768.
7. Seong J, Keum KC, Han KH et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999 43 : 393 397.
8. Iwamiya T, Sawada S, Ohta Y. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother. Pharmacol. 1994 33 (Suppl.) S134 8.
9. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999 29 : 62 7.
10. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am. J. Gastroenterol. 2005 100 : 1995 2004.
11. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann. Surg. 1990 211 : 277 287.
12. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998 28 : 751 755.
13. Uka K, Aikata H, Takaki S et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World. J. Gastroenterol. 2007 13 : 414 420.
14. Fujii T, Takayasu K, Muramatsu Y et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn. J. Clin. Oncol. 1993 23 : 105 109.
15. Uka K, Aikata H, Takaki S et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 2007 42 : 845 853.
16. Uka K, Aikata H, Takaki S et al. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver. Int. 2007 27 : 1209 1216.
17. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002 94 : 435 442. (Pubitemid 34081374)
18. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br. J. Cancer. 2005 93 : 557 564.
19. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006 106 : 1990 1997.
20. Natsuizaka M, Omura T, Akaike T et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J. Gastroenterol. Hepatol. 2005 20 : 1781 1787.
21. Ikai I, Hatano E, Hasegawa S et al. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J. Am. Coll. Surg. 2006 202 : 431 438.
22. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982 5 : 649 655.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer. Inst. 2000 92 : 205 216.
24. Ishii H, Furuse J, Kinoshita T et al. Extrahepatic spread from hepatocellular carcinoma: who are candidates for aggressive anti-cancer treatment? Jpn. J. Clin. Oncol. 2004 34 : 733 739.
25. Wada H, Nagano H, Noda T et al. Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. J. Gastroenterol. 2007 42 : 501 506.
26. Uka K, Aikata H, Mori N et al. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology. 2008 75 : 8 16.
27. Nakamura M, Nagano H, Marubashi S et al. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008 112 : 1765 1771.